Major Revision of USP Chapter <1724> Semisolid Drug Products Performance Tests Published for Comment
Recommendation
Tuesday, 14 January 2025 13.00 - 17.30 h
In the current Pharmacopeial Forum, PF 48(3), a major revision of USP general chapter <1724> Semisolid Drug Products—Performance Tests is being proposed. This proposal is based on the version of the chapter official as of August 01, 2013.
The scope of the currently valid chapter is "to provide general information for performance testing of semisolid drug products, various types of equipment employed for such testing, and potential applications of the performance testing". Compared to the currently valid version, the scope of the new draft has been expanded. It also includes in vitro release test (IVRT) as well as in vitro permeation test (IVPT) methods, with discussions on experimental design, method development, and validation.
According to the briefing notes, the proposal further includes "new information on appropriate contexts of use for IVRT and IVPT studies, and a guide for selecting an appropriate test method (IVRT or IVPT) depending upon the goal of the experiment." In addition, the text contains "revise information related to test equipment for IVRT and IVPT studies, with general discussions on setup and qualification considerations for vertical diffusion cells, immersion cells, and flow-through diffusion cells."
The text was also adapted and expanded in other parts. All these changes are noticeable in a more detailed structuring of the subchapters. The chapter is now divided into the following sections:
- Scope
- Introduction
- In vitro release test (IVRT)
- In vitro permeation test (IVPT)
- Equipment
The draft of the revised chapter is available on PF Online. (Please note: a one-time registration is required to access the Pharmacopeial Forum. Comments can be submitted until July 31, 2022.
Related GMP News
11.12.2024Another FDA Warning Letter Based on Review of Records
04.12.2024FDA Warning Letter to South African OTC Drug Manufacturer
02.12.2024How to keep Analytical Systems Current and Compliant
27.11.2024FDA Inspections in the EU: Warning Letter to Italian OTC Drug Manufacturer
21.11.2024New GMP Journal Article on Analytical Instrument Qualification and System Validation
21.11.2024FDA Warns Chinese OTC Drug Manufacturer Following Review of Records